Liposomal nanovaccine containing α-galactosylceramide and ganglioside gm3 stimulates robust cd8+ t cell responses via cd169+ macrophages and cdc1

Joanna Grabowska, Dorian A. Stolk, Maarten K. Nijen Twilhaar, Martino Ambrosini, Gert Storm, Hans J. van der Vliet, Tanja D. de Gruijl, Yvette van Kooyk, Joke M.M. Den Haan*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

4 Downloads (Pure)


Successful anti-cancer vaccines aim to prime and reinvigorate cytotoxic T cells and should therefore comprise a potent antigen and adjuvant. Antigen targeting to splenic CD169+ macrophages was shown to induce robust CD8+ T cell responses via antigen transfer to cDC1. Interestingly, CD169+ macrophages can also activate type I natural killer T-cells (NKT). NKT activation via ligands such as α-galactosylceramide (αGC) serve as natural adjuvants through dendritic cell activation. Here, we incorporated ganglioside GM3 and αGC in ovalbumin (OVA) protein-containing liposomes to achieve both CD169+ targeting and superior DC activation. The systemic delivery of GM3-αGC-OVA liposomes resulted in specific uptake by splenic CD169+ macrophages, stimulated strong IFNγ production by NKT and NK cells and coincided with the maturation of cDC1 and significant IL-12 production. Strikingly, superior induction of OVA-specific CD8+ T cells was detected after immunization with GM3-αGC-OVA liposomes. CD8+ T cell activation, but not B cell activation, was dependent on CD169+ macrophages and cDC1, while activation of NKT and NK cells were partially mediated by cDC1. In summary, GM3-αGC antigen-containing liposomes are a potent vaccination platform that promotes the interaction between different immune cell populations, resulting in strong adaptive immunity and therefore emerge as a promising anti-cancer vaccination strategy.

Original languageEnglish
Article number56
Pages (from-to)1-19
Number of pages19
Issue number1
Publication statusPublished - 16 Jan 2021


  • Alpha galactosylceramide
  • Anti-tumor
  • CD169 macrophage
  • CDC1
  • Ganglioside GM3
  • Invariant natural killer T cell
  • Liposomes
  • Vaccination
  • cDC1
  • liposomes
  • invariant natural killer T cell
  • anti-tumor
  • ganglioside GM3
  • alpha galactosylceramide
  • vaccination

Fingerprint Dive into the research topics of 'Liposomal nanovaccine containing α-galactosylceramide and ganglioside gm3 stimulates robust cd8<sup>+</sup> t cell responses via cd169<sup>+</sup> macrophages and cdc1'. Together they form a unique fingerprint.

Cite this